Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, with a specific reporting date of February 12, 2021. The document serves as a transaction notification regarding the granting of awards under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP) to Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to the valuation of specific equity awards granted to executives:
- Ordinary Shares Price: GBP 12.77 per share.
- American Depositary Shares (ADS) Price: USD 35.75 per ADS.
- Total Awards: The filing details specific share volumes granted to 15 executives, ranging from 4,019 to 45,779 units depending on the individual and instrument type.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents the execution of a pre-approved compensation plan (DABP) where Executive Directors defer 50% of bonuses and other Corporate Executive Team members defer 25% into shares or ADSs for a three-year period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a regulatory disclosure of a specific transaction type (Deferred Bonus Awards) and does not address the company's outlook or unusual items.
Investor Verification Checklist
- Verify the total number of shares/ADSs granted to PDMRs against the company's annual proxy statement or equity compensation report.
- Confirm the three-year deferral period and vesting conditions associated with the 2017 Deferred Annual Bonus Plan.
- Check the market price of GSK Ordinary Shares and ADSs on February 10, 2021, to validate the transaction prices of GBP 12.77 and USD 35.75.
- Review the specific roles of the 15 named executives to understand the distribution of deferred compensation across the organization.